Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
financials were beautiful....manipulation like this is not.
when did Q1 come out??
November, 2018 can't come soon enough.
Charles Ernest Grassley (born September 17, 1933) is an American politician serving as the senior United States Senator from Iowa, first elected in 1980. A member of the Republican Party,
He's received millions in contributions from big pharma as listed on his website.
The Net Loss: Significant estimates and assumptions are used in the determination of the fair values of these derivative financial instruments. The fair values are determined in part by, and will fluctuate with, the market value of our stock. If the market price of our stock increases during a period, the fair value of the derivatives is expected to increase and will adversely affect our earnings. A decline in the market price of the stock will cause a decrease in fair value of the derivatives and have a positive impact to earnings. The change in the fair value of these derivative financial instruments has no impact on our cash flows.
That 1.9M loss was due to the change in liability for options granted to officers and other stakeholders as a result of the substantial increase[color=red][/color] in Stock price over 2017. It has nothing to do with operations. If you take that liability out, the actual loss is lower by 31% than in 2016.
And that loss was already reported in 10Q in march 2017. Been built into pps.
WALL IS DOWN...SLAP IT!!!!!
Somebody just scarfed up that whole wall....9s today!!
and they dropped it to .0755
CDEL quarter mil on bid .0778
So DON"T sell...plain and simple.
It's only a 15k ask
50K to 10 cents
they're required to do that.
wasn't too soon...bids filled.
Um...no.
So that the news of great financials has time to circulate...then boom!
let them bid sit...they'll be chasing 8's later.
Agreed...Should be a good day.
Financials will likely be released AH...people will want to get as much as they can so they don't chase next week.
REAL-TIME LEVEL 2 QUOTE
BID PRICE SIZE TIME
CDEL 0.0652 36,000 11:34
CANT 0.0644 10,000 11:03
CSTI 0.0631 10,000 09:43
NITE 0.0631 10,000 10:58
ETRF 0.062 16,219 11:04
VNDM 0.062 10,000 03/27
ASCM 0.0576 10,000 03/23
VERT 0.051 10,000 03/27
AEXG 0.031 10,000 02/12
BMIC 0.001 10,000 08/17
MAXM 0.0001 10,000 07:35
PUMA 0.0001 10,000 10:17
ASK PRICE SIZE TIME
NITE 0.0671 22,000 11:07
ETRF 0.0675 10,000 11:34
CANT 0.068 25,000 11:07
CDEL 0.072 11,927 11:34
VERT 0.0798 10,000 03/27
ASCM 0.0815 10,000 03/22
AEXG 0.10 5,000 12/21
VNDM 0.10 5,000 03/27
CSTI 0.11 12,704 10:33
PUMA 0.11 5,000 10:17
MAXM 0.18 50,000 09:30
BMIC 1.00 100 05/16
OMG...that's horrible news.....oh wait....that's not news.
Still no financials....wth!?
you must be on it to believe that.
trade war has nothing to do with this stock. The Dow has nothing to do with this stock.
that was a coordinated attack.
REAL-TIME LEVEL 2 QUOTE
MPID BID PRICE SIZE TIME
CANT 0.077 10,000 14:26
CSTI 0.0765 11,797 14:19
NITE 0.0765 10,000 14:20
CDEL 0.076 10,000 14:26
VERT 0.0731 10,000 12:48
ETRF 0.0725 150,000 14:18
ASCM 0.0725 10,000 13:52
PUMA 0.07 10,000 09:32
VNDM 0.048 10,000 03/21
AEXG 0.031 10,000 02/12
BMIC 0.001 10,000 08/17
MAXM 0.0001 10,000 07:35
MPID ASK PRICE SIZE TIME
NITE 0.0786 25,000 14:15
CSTI 0.08 25,000 14:17
ASCM 0.0815 10,000 12:45
CANT 0.082 50,000 14:17
ETRF 0.085 75,000 14:25
CDEL 0.085 12,000 14:26
AEXG 0.10 5,000 12/21
VNDM 0.10 5,000 03/21
VERT 0.10 5,000 12:48
PUMA 0.12 5,000 09:32
BMIC 1.00 100 05/16
MAXM 200.00 1 07:35
nothing has changed from yesterday....let's go!!!
good going. I was lucky to get 20 K this morning at the dip at .0681
I don't see any wall.
REAL-TIME LEVEL 2 QUOTE
MPID BID PRICE SIZE TIME
VERT 0.0675 10,000 14:52
CDEL 0.0675 10,000 14:52
CANT 0.0672 10,000 14:52
NITE 0.0671 10,000 14:50
ETRF 0.0668 40,000 14:45
CSTI 0.065 25,000 13:20
VNDM 0.048 10,000 03/20
AEXG 0.031 10,000 02/12
PUMA 0.03 10,000 08:10
BMIC 0.001 10,000 08/17
MAXM 0.0001 10,000 07:35
OTCX U 0 13:21
MPID ASK PRICE SIZE TIME
CANT 0.0678 10,000 14:52
VERT 0.0678 10,000 14:52
ETRF 0.068 10,000 14:39
CDEL 0.07 68,160 14:52
CSTI 0.07 35,000 13:36
PUMA 0.095 10,000 08:10
AEXG 0.10 5,000 12/21
VNDM 0.10 5,000 03/20
NITE 0.10 5,000 14:52
BMIC 1.00 100 05/16
MAXM 200.00 1 07:35
OTCX U 0 11:23
EXACTLY - NOT TO MENTION
(CNN)Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the development of stem cell therapies proved to be safe and effective.
Dr. Scott Gottlieb, the FDA commissioner, and Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, co-authored a new paper detailing the delicate balance between safety and innovation when it comes to the possibilities of using stem cells in medicine.
https://www.cnn.com/2018/03/08/health/stem-cell-therapy-fda-bn/index.html
DAMN. CANT PLAYING BLOCKER at 6 NEW WALL 2 mins ago.
Annual Financials for U.S. Stem Cell Inc.
View Ratios
Fiscal year is January-December. All values USD millions.
2012 2013 2014 2015 2016
Sales/Revenue 61,109 96,085 2.06M 2.19M 3.08M
Cost of Goods 15,659 33,021 849,431 978,283 977,794
That's called increased revenues and increasing profits.
Can't wait for tomorrow. Looking for well over 5M in sales.
WALL IS DOWN!!! GO FOR IT!!
Great slap whoever you were!!! Closing Green - READY FOR THOSE FINS!!!
hit piece...ad.
TRY AND PAY ATTENTION.
Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the development of stem cell therapies proved to be safe and effective.
Dr. Scott Gottlieb, the FDA commissioner, and Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, co-authored a new paper detailing the delicate balance between safety and innovation when it comes to the possibilities of using stem cells in medicine.
"Our aim is to refashion our traditional tools for regulation to meet the challenges and opportunities presented by such highly innovative products as cell-based regenerative medicine," they wrote in the paper, published Thursday in the New England Journal of Medicine.
Divisions run deep over how to regulate stem cell clinics
Divisions run deep over how to regulate stem cell clinics
Stem cells have the potential to develop into many cell types in the body. Some studies suggest that stem cells may help the nearly blind to see and could reverse signs of aging. Research has even explored using stem cells to create red blood cells to replenish blood shortages during emergencies.
"However, despite the increasingly widespread use of stem cells in techniques being labeled as regenerative medicine, clinical benefit has not been clearly shown in most instances," Gottlieb and Marks wrote.
The FDA hopes to change that, while continuing efforts to regulate the industry.
'A sweet spot of stem cell oversight'
"This more reflects an update from the FDA on where their thinking stands on stem cells. I don't see it as backing down from the hoped-for stepping up of FDA oversight of clinics," said Paul Knoepfler, professor of cell biology and human anatomy at the University of California, Davis School of Medicine, who wrote a blog post about the new paper.
"The FDA seems to be saying they want to find a sweet spot of stem cell oversight where they encourage innovation by good citizens and yet also carefully regulate this sphere as well as encouraging those interested in transplanting stem cells into patients to work with the FDA," he said.
Stem cell study offers hope for ALS
Stem cell study offers hope for ALS 08:29
Knoepfler co-authored a paper, published in the journal Cell Stem Cell in 2016, that found unapproved stem cell interventions being marketed at 570 clinics across the US. "Hot spot" cities where there were clusters of clinics included Beverly Hills, California; New York; San Antonio; Los Angeles; Austin, Texas; Scottsdale, Arizona, and Phoenix.
Although Gottlieb and Marks didn't mention clinics in their paper, they noted that facilitating the availability of safe and effective therapies was part of the FDA's oversight of regenerative medicine products, including new stem cell therapies.
The FDA will provide tools to encourage individual or small groups of physicians to collaborate in support of the development of a stem cell or other regenerative medicine product, they wrote.
A milestone in stem cell research
A milestone in stem cell research 01:50
Gottlieb and Marks also said the FDA is encouraging investigators who are involved in such innovative product development to engage in dialogue with the agency early on in the research process.
"It feels like the FDA leadership is in essence telling them, 'Do the right thing, and we'll help you with a trial, even if you aren't a big university or company,' " Knoepfler said. "It's reassuring to see though that the FDA still emphasizes it is crucial to have data and follow the rules."
The FDA held a Grand Rounds webcast on Thursday detailing how its scientists are examining strategies and methods to predict the reliability of how certain cell-based therapies will perform in humans.
The ability to make such predictions could be a big step toward getting safe and effective FDA-approved treatments to patients in the future.
Predicting the future
For many investigational stem cell-based products, it remains unclear whether the measurements currently used to characterize products will predict their clinical effectiveness, according to the FDA.
As of now, stem cell-based products submitted to the FDA in clinical trial proposals are characterized using a small number of cell surface markers and simple measures of cell product activity -- but is that enough to truly predict clinical outcomes?
Answering that question has become one of many focuses of the FDA's Multipotent Stromal Cell Consortium, a large team of scientists studying adult multipotent stromal cells. These are stem cells that can differentiate into a variety of cell types and could contribute to tissue repair or help replace, restore or regenerate other parts of the body.
Steven Bauer, chief of the cellular and tissues therapy branch in the Center for Biologics Evaluation and Research, gave the keynote presentation at Thursday's Grand Rounds and focused on how, when multipotent stromal cells are studied for use as therapies, predictability is key.
"We can use some of this information to help generate standards in this field," he said. "There is a tremendous amount of interest now in developing standards that will facilitate the development of regenerative medicine and products."
99.99% of the OTC is pre-profit.
less than 10% are making revenues, and a fraction of that are increasing revenues 6 quarters in a row while clearing up their balance sheets, in a potentially limitless emerging growth market.
Stock trading is based on speculation...not today's numbers. Want to look to the past for trends. The trend is expansion, higher revs, lower debts.
Common sense...
when it hits over .1 it'll cool down...should be there now.
34K to .05.